Last Updated : May 12, 2024
The latest CADTH Reimbursement Review reports are posted to this page. CADTH reimbursement reviews are comprehensive assessments of the clinical effectiveness and cost-effectiveness, as well as patient and clinician perspectives, of a drug or drug class. The assessments inform non-binding recommendations that help guide the reimbursement decisions of Canada's federal, provincial, and territorial governments, with the exception of Quebec. Implementation advice and funding algorithms are provided where applicable.
Brand Name | Generic Name Sort descending | Therapeutic Area | Recommendation Type | Project Status | Date Submission Received | Date Recommendation Issued |
---|---|---|---|---|---|---|
Keytruda | Pembrolizumab | Squamous NSCLC | Reimburse with clinical criteria and/or conditions | Complete | ||
Keytruda | Pembrolizumab | Melanoma Adjuvant Treatment | Reimburse with clinical criteria and/or conditions | Complete | ||
Keytruda | Pembrolizumab | MUC First line | Do not reimburse | Complete | ||
Keytruda | pembrolizumab | Triple-negative breast cancer | Reimburse with clinical criteria and/or conditions | Complete | ||
Keytruda | Pembrolizumab | Metastatic Melanoma | Reimburse with clinical criteria and/or conditions | Complete | ||
N/A | Pembrolizumab | Melanoma (Skin) | Active | |||
Keytruda | Pembrolizumab | Advanced non-small cell lung carcinoma (first line) | Reimburse with clinical criteria and/or conditions | Complete | ||
Keytruda | Pembrolizumab | Non-Small Cell Lung Cancer | Reimburse with clinical criteria and/or conditions | Complete | ||
Keytruda | Pembrolizumab | CADTH is unable to recommend reimbursement as a submission was not filed by the manufacturer | Not filed | |||
Keytruda | Pembrolizumab | head and neck squamous cell carcinoma (HNSCC) | Reimburse with clinical criteria and/or conditions | Complete |